CureVac AG, a company that has been active in the messenger RNA space for more than 16 years, is on the prowl for more pharma partners in order to advance its pipeline programs in prostate cancer and non-small cell lung cancer (NSCLC) to the next level and to widen its program into other indications.
Freshly Financed CureVac Seeks Partner To Keep Up In mRNA
German biopharmaceutical company CureVac, which secured $29.5m via a new financing round this week, talks to Scrip on the sidelines of the BIO-Europe partnering conference in Cologne about development plans for its mRNA cancer vaccine technology and its goals for 2017 – which include securing a new pharma partner.
More from Business
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Public Company Edition: Biohaven secured $250m up front from Oberland Capital to support its future US troriluzole launch after pulling its EU filing. Also, Procaps arranged $130m in private equity and Rezolute grossed $96.9m in a rare follow-on offering, among other financings.
• By
On Lilly’s Q1 earnings call, CEO David Ricks voiced concerns about the Trump Administration’s tariff policy, which he said could adversely affect Lilly and the industry as a whole.
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
More from Scrip
• By
While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.